Is the regulatory world ready for 'nanosimilars'?
This article was originally published in SRA
In the beginning there were generics. Then came biosimilars. Now the regulatory world is preparing for the appearance of a new kind of follow-on product: "nanosimilars", or versions of the first generation of nanomedicines, whose patents are on the way to expiry.
You may also be interested in...
While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.
The pharmaceutical industry and other stakeholders have taken part in the launch event for a new initiative intended to tackle issues that have been amplified by the COVID-19 pandemic, such as supply chain resilience and medicine shortages. The project has drawn a mixed response from industry bodies.
The MHRA is losing no time in getting its much heralded “new era” of medicines regulation up and running.